Abstracts tagged "canakinumab"

Abstract Number: 258 • 2015 ACR/ARHP Annual Meeting
Quality of Life Changes with Canakinumab Therapy in Adults with Colchicine Resistant FMF
Ahmet Gul¹, Huri Ozdogan², Ozgur Kasapcopur³, Burak Erer⁴, Serdal Ugurlu⁵, S. Sevgi⁶ and Soner Turgay⁷, ¹Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ³Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Professor of Pediatric Rheumatology, Istanbul, Turkey, ⁴Istanbul Faculty of Medicine, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ⁵Rheumatology, Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ⁶Novartis Pharma, Istanbul, Turkey, ⁷Medical, Novartis Pharma, İstanbul, Turkey
Background/Purpose: Introduction:Familial Mediterranean Fever (FMF), the most common form of the hereditary autoinflammatory disorders, is characterized by recurrent attacks of fever along with serosal or…
Abstract Number: 262 • 2015 ACR/ARHP Annual Meeting
Canakinumab Therapy in Patients with Familial Mediterranean Fever
Serdal Ugurlu¹, Emire Seyahi², Gulen Hatemi², Aysa Hacioglu¹, Humeyra Ozcan¹, Fatma Nihan Akkoc¹ and Huri Ozdogan², ¹Rheumatology, Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey
Background/Purpose: It has been reported that Canakinumab reduced the frequency of attacks in patients with Familial Mediterranean Fever (FMF) resistant to colchicine with no apparent…
Abstract Number: 2344 • 2015 ACR/ARHP Annual Meeting
A 3-Year Follow-up Study of Canakinumab in Frequently Flaring Gouty Arthritis Patients, Contraindicated, Intolerant, or Unresponsive to Nonsteroidal Anti-Inflammatory Drugs and/or Colchicine
Naomi Schlesinger¹, Thomas Bardin^2,3, Mark Bloch⁴, Karine Lheritier⁵, Uwe Machein⁵, Guido Junge⁵, Alexander So⁶ and Rieke Alten⁷, ¹Medicine, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, ²Hopital Lariboisière, Paris, France, ³Rhumatology Departement, Hôpital Lariboisière, Paris, France, ⁴Holdsworth House Medical Practice, Sydney, Australia, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶CHU Vaudois, University of Lausanne, Lausanne, Switzerland, ⁷Charité Univ Medicine, Berlin, Germany
Background/Purpose: Although anti-inflammatory drugs such as nonsteroidal anti-inflammatory drugs and colchicine are the recommended treatment options for pain and inflammation management in patients (pts) with…
Abstract Number: 2345 • 2015 ACR/ARHP Annual Meeting
Canakinumab Liquid Formulation in Acute Gouty Arthritis Patients: Long-Term Safety and Efficacy Results from a 36-Week Extension Study
Prashanth Sunkureddi¹, Rüdiger Moericke², Edith Tóth³, Jacques P Brown⁴, Uwe Machein⁵, Karine Lheritier⁵, Guido Junge⁵ and Alan J Kivitz⁶, ¹Clear Lake Rheumatology, Nassau Bay, TX, ²Institut für Präventive Medizin & Klinische Forschung GbR, Magdeburg, Germany, ³Flór Francis Hospital Rheumatology Department, Kistarcsa, Hungary, ⁴Centre Hospitalier de l'Université Laval (CHUL), Quebec City, QC, Canada, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Patients with gouty arthritis (GA) experience frequent flares with pain and inflammation. The limited available treatment options and typical comorbidities warrant effective alternative treatments1.…
Abstract Number: 1230 • 2014 ACR/ARHP Annual Meeting
Efficacy of Interleukin-1 Targeting Drugs in Familial Mediterranean Fever Patients
Pinar Cetin¹, Ismail Sari¹, Betul Sozeri², Ozlem Cam², Merih Birlik¹, Fatos Onen¹, Nurullah Akkoc¹ and Servet Akar¹, ¹Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, ²Pediatrics, Ege University School of Medicine, Izmir, Turkey
Background/Purpose Familial Mediterranean fever (FMF) is an autosomal-recessive autoinflammatory disorder characterized by recurrent episodes of fever accompanied by sterile peritonitis. The most devastating complication of…
Abstract Number: 833 • 2014 ACR/ARHP Annual Meeting
Canakinumab Use in Patients with Cryopyrin-Associated Periodic Syndrome: Interim Safety and Efficacy Results from Beta-Confident Registry
Hal M. Hoffman¹, Jasmin B. Kuemmerle-Deschner², Philip N. Hawkins³, T. van der Poll⁴, Ulrich A. Walker⁵, Ken Abrams⁶ and Hugh H. Tilson⁷, ¹Division of Allergy, Immunology and Rheumatology, University of California at San Diego, La Jolla, CA, ²University Hospital Tuebingen, Tuebingen, Germany, ³University College London Medical School, London, United Kingdom, ⁴Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁵Department of Rheumatology, University Hospital Basel, Basel, Switzerland, Basel, Switzerland, ⁶Novartis Pharmaceutical Corporation, East Hanover, NJ, ⁷Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC
Background/Purpose The three phenotypes in the order of severity: familial cold auto-inflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), and chronic infantile neurologic cutaneous and articular syndrome/neonatal…
Abstract Number: 305 • 2014 ACR/ARHP Annual Meeting
Understanding the Molecular Pathogenesis of and Response to Canakinumab Treatment in TNF Receptor-Associated Periodic Syndrome By Gene Expression Profiling of Whole Blood from Patients
R. Torene¹, M. Gattorno², H. Lachmann³, L. Obici⁴, A. Meini⁵, V. Tormey⁶, R. Caorsi⁷, L. Baeriswyl⁸, U. Affentranger⁸, S. Starck-Schwertz⁸, M. Letzkus⁸, N. Hartmann⁸, K. Abrams⁹ and N. Nirmala¹, ¹Novartis Institutes for BioMedical Research, Cambridge, MA, ²Pediatric Rheumatology, G. Gaslini Institute, Genova, Italy, ³Royal Free Hospital, London, United Kingdom, ⁴Amyloid Centre, IRCCS Policlinico San Matteo, Pavia, Italy, ⁵Pediatric Clinic, Spedali Civili, Brescia, Italy, ⁶Galway University Hospitals, Galway, Ireland, ⁷Second Division of Paediatrics, G. Gaslini Institute, Genova, Italy, ⁸Novartis Institutes for BioMedical Research, Basel, Switzerland, ⁹Novartis Pharmaceutical Corporation, East Hanover, NJ
Background/Purpose: TNF receptor-associated periodic syndrome (TRAPS) is an autoinflammatory disease causing unprovoked fevers, myalgia, abdominal pain, rash, headaches, and, in severe cases, AA amyloidosis. It…
Abstract Number: 159 • 2014 ACR/ARHP Annual Meeting
Canakinumab in Frequently Flaring Gouty Arthritis Patients, Contraindicated, Intolerant or Unresponsive to non-Steriodal Anti-Inflammatory drugs and/or Colchicine: Safety and Efficacy Results from Long Term Follow-up
Naomi Schlesinger¹, Rieke Alten², Thomas Bardin³, H. Ralph Schumacher Jr.⁴, Mark Bloch⁵, Karine Lheritier⁶, Dominik Richard⁶, Andrea Stancati⁷ and Alexander So⁸, ¹Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, ²Charité University Medicine, Berlin, Germany, ³Clinique de Rhumatologie. Service de Rhumatologie. Centre Viggo Petersen., Hôpital Lariboisière, Paris, France, ⁴University of Pennsylvania VA Medical Center, Philadelphia, PA, ⁵Holdsworth House Medical Practice, Sydney, Australia, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Campus Forum 1, Novartis Pharma AG, Basel, Switzerland, ⁸Rheumatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland
Background/Purpose Frequently flaring acute gouty arthritis (GA) patients (pts), in whom NSAIDs and/or colchicine are contraindicated, not tolerated or ineffective, need effective alternative treatments.1 Canakinumab…
Abstract Number: 2747 • 2013 ACR/ARHP Annual Meeting
Canakinumab Treatment In Schnitzler’s Syndrome: A Multi-Center Randomized Placebo-Controlled 4-Month Study
Karoline Krause, Karsten Weller, Martin Metz and Marcus Maurer, Dept. of Dermatology and Allergy, Allergie-Centrum-Charité, Charité – Universitätsmedizin Berlin, Germany, Berlin, Germany
Background/Purpose: Schnitzler’s syndrome (SchS) is an adult-onset autoinflammatory disease characterized by urticarial exanthema and monoclonal gammopathy in combination with episodes of fever, arthralgia, fatigue, and…
Abstract Number: 1204 • 2013 ACR/ARHP Annual Meeting
Model-Based Pharmacokinetics Of Canakinumab and Pharmacodynamics Of IL-1Beta Binding In Cryopyrin Associated Periodic Syndromes, a Step Towards Personalized Medicine
Aurélie Gautier¹, Phil Lowe¹, Andrej Skerjanec¹, Phil McKernan¹, Wenping Wang² and Olivier Luttringer¹, ¹Novartis Pharma AG, Basel, Switzerland, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Cryopyrin-associated periodic syndrome (CAPS), comprises of extremely rare, inherited auto-inflammatory diseases, including the mildest form familial cold auto-inflammatory syndrome (FCAS), the more severe Muckle-Wells…
Abstract Number: 1208 • 2013 ACR/ARHP Annual Meeting
Canakinumab In Patients With FMF
Serdal Ugurlu¹, Emire Seyahi¹, Gulen Hatemi², Ayse Hacioglu² and Huri Ozdogan², ¹Division of Rheumatology,Department of Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey
Background/Purpose: In a recent pilot study, it was reported that Canakinumab reduced the frequency of attacks in 9 patients with Familial Mediterranean Fever (FMF) resistant…
Abstract Number: 269 • 2013 ACR/ARHP Annual Meeting
Marked Improvement In Patient Reported Outcomes Of Children With Active Systemic Juvenile Idiopathic Arthritis With Canakinumab Treatment – Results Of The Phase III Program
Rayfel Schneider¹, Hermine Brunner¹, Nicolino Ruperto², Nico Wulffraat², Pierre Quartier³, Riva Brik², Liza McCann², Helen E. Foster², Michael Frosch², Valeria Gerloni², Liora Harel², Claudio Len², Kristin Houghton¹, Rik Joos², Ken Abrams⁴, Karine Lheritier⁵, Sophia Kessabi⁵, Alberto Martini² and Daniel J. Lovell¹, ¹Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, ²Pediatric Rheumatology International Trials Organization (PRINTO)-Istituto Gaslini, Genova, Italy, ³Necker-Enfants Malades Hospital, Paris, France, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Efficacy and safety of canakinumab (CAN), a selective, fully human, anti-interleukin-1β monoclonal antibody, in systemic juvenile idiopathic arthritis (SJIA) patients has been demonstrated in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].